Bioverativ
Market Access/ News/ News/ R&D/ Top stories/ UK & Europe
Sanofi says biotech acquisitions will help overcome diabetes decline
Andrew McConaghie
Ablynx, Bioverativ, haeomophilia, Sanofi
0 Comment
After losing out on two big deals, Sanofi to buy Bioverativ for $11.6bn
Richard Staines
Bioverativ, haemophilia, haemophilia A, haemophilia B, Sanofi
0 Comment
French pharma makes move into haemophilia market.
Despite Trump price concerns, JP Morgan event anticipates M&A boom
Richard Staines
Actelion, Biogen, Bioverativ, Johnson & Johnson, JP Morgan, M&A, Valeant
0 Comment
2017 could be a bumper year for M&A – but Trump’s price control threats dominate
News/ R&D/ Sales and Marketing
Biogen’s haemophilia spin-out Bioverativ to launch early 2017
Andrew McConaghie
Biogen, Bioverativ, haemophilia
0 Comment
Coming antibody drugs and gene therapy could transform treatment
New haemophilia drug Elocta approved in Europe
Linda Banks
Bio, Bioverativ, Elocta, haemophilia, SOBI
0 Comment